Liezl Gambe - Author on Grafa
Tudo
Celcuity jumps as FDA grants priority review for breast cancer drug
Celcuity (NASDAQ:CELC) shares rose in premarket trading Tuesday after the U.S. Food and Drug Administration accepted the New Drug Application for gedatolisib, a potential first-in-class therapy for patients with advanced breast cancer.
3M caps turnaround year with margin expansion, eyes stronger 2026
3M (NYSE:MMM) delivered fourth-quarter results on Tuesday that underscored the industrial giant’s successful shift toward operational leaness, as adjusted operating margins reached 21.1%—a 140-basis-point improvement over the previous year.
Peoples Bancorp posts record Q4 net income of $31.8M
Marietta, Ohio-based Peoples Bancorp (NASDAQ:PEBO) reported strong fourth-quarter 2025 financial results, highlighted by record net income of $31.8 million, or $0.89 per diluted share, compared with $26.9 million ($0.76 per share) in the fourth quarter of 2024 and $29.5 million ($0.83 per share) in the third quarter of 2025.
ImmunityBio nears finish line for ANKTIVA expansion in bladder cancer
ImmunityBio (NASDAQ:IBRX) is moving toward a significant label expansion for its first-in-class immunotherapy, ANKTIVA® (nogapendekin alfa inbakicept), following a pivotal Type B meeting with the U.S. Food and Drug Administration (FDA).










-640x358.jpg&w=1200&q=75)